Hiramatsu K, Sugimoto M, Kamei S, Hoshino M, Kinoshita K, Iwasaki K, Kawakita M
Department of Physiological Chemistry, Tokyo Metropolitan Institute of Medical Science, Japan.
J Cancer Res Clin Oncol. 1997;123(10):539-45. doi: 10.1007/s004320050102.
Recently, we found N1,N8-diacetylspermidine (Ac2Spd) and N1,N12-diacetylspermine (Ac2Spm) in human urine, and noted that their amount increased significantly in patients with urogenital malignancies. Previous findings that simultaneous reference to these diacetylpolyamines is useful in distinguishing cancer patients from healthy persons were confirmed by more recent analytical data on urine samples from several cancer patients. Further examination revealed that urinary Ac2Spm and Ac2Spd tended to decrease when cancer patients were treated and entered partial remission. In cases where the Ac2Spm and Ac2Spd levels were normal or near-normal after treatments, the prognosis of the patients was generally good. In contrast, when their level remained far above the normal limits after apparently effective treatment, the prognosis of the patients was poor. When a patient is in remission for more than 3 years, urinary levels of both Ac2Spm and Ac2Spd are stabilized and stay below the normal limits, with rare exceptions. The recurrence of a cancer as well as the complication of a second one during the period of follow-up examination was accompanied by elevation of urinary diacetylpolyamines. These observations indicate that urinary Ac2Spm and Ac2Spd are useful as prognostic indicators after treatment and during follow-up examination of cancer patients.
最近，我们在人尿液中发现了N1,N8 - 二乙酰亚精胺（Ac2Spd）和N1,N12 - 二乙酰精胺（Ac2Spm），并注意到它们在泌尿生殖系统恶性肿瘤患者中的含量显著增加。先前关于同时检测这些二乙酰多胺有助于区分癌症患者和健康人的研究结果，被来自几位癌症患者尿液样本的最新分析数据所证实。进一步检查发现，癌症患者接受治疗并进入部分缓解期时，尿液中的Ac2Spm和Ac2Spd往往会降低。在治疗后Ac2Spm和Ac2Spd水平正常或接近正常的情况下，患者的预后通常较好。相反，在经过明显有效的治疗后，如果它们的水平仍远高于正常范围，患者的预后则较差。当患者缓解超过3年时，尿液中Ac2Spm和Ac2Spd的水平会稳定下来，并保持在正常范围以下，极少有例外情况。在随访检查期间，癌症复发以及并发第二种癌症时，尿液中二乙酰多胺的含量会升高。这些观察结果表明，尿液中的Ac2Spm和Ac2Spd可作为癌症患者治疗后及随访检查期间的预后指标。
